Next generation of CAR T: improving efficacy and availability

Prof. Dr. Maria Themeli (MD)Amsterdam UMC, The Netherlands



Thursday 14th September 2 pm – 3:30 pm



leslokaal 5.2 Campus Heymans/UZ B3, 5th floor



About

Dr Themeli studied Medicine in the University of Patras, Greece. After graduating, she did her PhD at the Bone Marrow Transplantation laboratory in the University of Patras Medical School under the supervision of Prof. Alexandros Spyridonidis. During this period she studied the long-term biological consequences of GvHD in epithelial tissues after allogeneic hematopoietic cell transplantation. After completing her PhD training Dr Themeli joined the lab of Dr Michel Sadelain at Memorial Sloan Kettering Cancer Center in New York. There she trained in the design and development of chimeric antigen receptor-engineered T cells (CAR T) and reported for the first time the use of induced pluripotent stem cells (iPSC) as an off-the-shelf source of therapeutic CAR T cells. In 2015 Dr Themeli received a Marie-Curie Individual Fellowship from the European Commission and joined the department of Hematology at Amsterdam UMC-location VUmc, where in 2017 she became Assistant Professor.

Invited by Prof. Dr. Bart Vandekerckhove Moderated by Prof. Dr. Tom Taghon







